Candriam Luxembourg S.C.A. boosted its stake in Selecta Biosciences, Inc. (NASDAQ:SELB) by 306.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 126,000 shares of the company’s stock after buying an additional 95,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Selecta Biosciences were worth $2,502,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SELB. UBS Group AG boosted its position in shares of Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock valued at $1,022,000 after buying an additional 65,938 shares during the last quarter. Hamilton Lane Advisors LLC boosted its position in Selecta Biosciences by 21.8% in the second quarter. Hamilton Lane Advisors LLC now owns 91,125 shares of the company’s stock worth $1,810,000 after buying an additional 16,292 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Selecta Biosciences by 83.1% in the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock worth $452,000 after buying an additional 14,332 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Selecta Biosciences during the first quarter worth $211,000. Finally, Hikari Power Ltd bought a new position in Selecta Biosciences during the first quarter worth $349,000. 46.27% of the stock is currently owned by institutional investors and hedge funds.

Selecta Biosciences, Inc. (NASDAQ:SELB) opened at 17.47 on Thursday. Selecta Biosciences, Inc. has a 12-month low of $10.26 and a 12-month high of $28.00. The company has a 50-day moving average price of $18.31 and a 200-day moving average price of $14.99.

Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Thursday, May 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.40. The company had revenue of $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 76.21% and a negative net margin of 715.40%. On average, equities analysts anticipate that Selecta Biosciences, Inc. will post ($3.34) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-boosts-stake-in-selecta-biosciences-inc-nasdaqselb/1468840.html.

A number of research firms have recently weighed in on SELB. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the company a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research raised Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 30th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $26.00.

In other Selecta Biosciences news, Director Edwin M. Kania, Jr. sold 266,795 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $14.00, for a total transaction of $3,735,130.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Lloyd P. Johnston sold 5,959 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $19.10, for a total value of $113,816.90. Following the sale, the chief operating officer now directly owns 7,565 shares of the company’s stock, valued at approximately $144,491.50. The disclosure for this sale can be found here. In the last three months, insiders have acquired 355,413 shares of company stock valued at $6,232,567 and have sold 321,819 shares valued at $4,765,494.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.